PSTEC - leads the smart grid
http://www.pstec.co.kr
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20160513004040
As we covered previously, the era that produces energy in the local area and consumes energy also in the local area comes soon. For this era, I think we need to develop the field of industries that are Energy Storage System (ESS) and smart grid altogether.
Generating electricity by using solar and wind power is irregular so that we have to maximize the efficiency of that throughout diverse electricity producers and electricity consumers who communicate each other bidirectionally to overcome the irregularity.
So I think the demand of Advanced Metering Infrastructure (AMI) that is produced by PSTEC will increase a lot. And PSTEC has provided AMIs to KEPCO, and they also had provided AMIs for a consortium of Jeju test site that is a kind of a smart grid model complex.
Sunday, July 9, 2017
Yungjin Pharm - develops COPD and rheumatoid arthritis medicine
Yungjin Pharm - develops COPD and rheumatoid arthritis medicine
http://www.yungjin.co.kr
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20160428000982
COPD is an abbreviation for Chronic Obstructive Pulmonary Disease and a category of a disease that blocks the respiratory tract causing lower the speed of the air in the lungs without any other pulmonary diseases or cardiac diseases. As COPD gets more severe, the number of pulmonary alveoli under the terminal bronchiole increases and pulmonary alveoli wall breaks, which is called pulmonary emphysema. We use the term COPD when we can't discriminate the two symptoms.
It is known that more than 90% of the causes of COPD are due to smoking. Air pollution, congenital diseases, and respiratory infections also account for the remaining 10%. COPD is the world's 4th disease and 7th disease in Korea in terms of death rate. The world market capitalization for COPD has been estimated to reach 26.9 billion USD (31.5 trillion KRW) by 2017.
http://www.medgadget.com/2015/06/asthma-and-copd-drug-market-global-industry-analysis-market-size-share-trends-growth-and-forecasts-2010-2017.html
Rheumatoid arthritis is known to occur in around 0.8% of the adult population. There is no way to prevent or cure this disease, but we can slow down the progress. The global market for rheumatoid arthritis medicine is expected to reach 80 billion USD (93.9 trillion KRW) by 2020.
http://www.prnewswire.com/news-releases/rheumatoid-arthritis-market-to-2020---a-crowded-market-characterized-by-modest-growth-300059888.html
Below is the development schedule for COPD and rheumatoid arthritis medicine of Yungjin Pharm.
Development Research for COPD medicine (YPL-001)
- US clinical IND approval (2013. 04)
- Completed US Phase 1 clinical trial (SAD) (2013. 07)
- Completed US Phase 1 clinical trial (MAD) (2014. 02)
- Completed US Phase 2 clinical trial (PoC) US SAB meeting (2014. 01)
- US Phase 2 clinical trial (PoC) approval (2014. 10)
- Registration of US clinical trial (PoC) examination information (ClinicalTrials.gov, 2014. 10)
- Completed of Kick-off-meeting of US Phase 2 clinical trial (PoC) (2014, 10)
- Completed US Phase 2 clinical trial (PoC) IRB approval (2014. 12, 2015 02)
- US Phase 2 clinical trials (PoC) Selected as a new phase drug development project (2015. 01; 3.7 billion KRW)
- US Phase 2 clinical trial (PoC) clinical initiation meeting (2015 03)
- US Phase 2 clinical trial (PoC) is in progress (2016 04 - present)
Development Research for rheumatoid arthritis medicine (YRA-1909)
- Natural product research to push into the US market (2014. 12 - 2019. 11, Ministry of Trade, Industry and Energy: 5 years 3.5 billion KRW)
- Completed mass production study
- Secured GAP mass cultivation site (3,300 square meter) and cultivation: Jangheung-gun, Jeollanam-do
- Research on ensuring equality of raw materials by origin
- Ingredient research (separation, purification etc.)
- Identification of three new ingredients (preparing for patent application)
- selected government task by Ministry of Trade, Industry and Energy (2014 04)
- Production of raw materials and nonclinical toxicity test (2015 02 - present)
- Domestic Phase 2 clinical trial approval (2015.12) and preparations to proceed (present)
Competitive Products for COPD medicine
As you can see the above, most of the treatments are required to be inhaled. The problem is that when the drug is inhaled, the drug delivery to the deep lungs is not very successful. Drug efficacy is only about relieving symptoms.
In contrast, COPD medicine from Yungjin Pharm is a natural-based treatment extracted from Mountain spike speedwell so that patients can easily take it. This medicine has the advantage that the drug acts on the entire lung effectively and aims to function as a cure agent instead of a symptom reliever.
Competitive products for rheumatoid arthritis
You should inject new rheumatoid drugs below as you can read.
- Etanercept: 25 mg by subcutaneous injection twice a week
- Infliximab: 3 to 5 mg / kg by intravenous injection at 0, 2, 6 week of administraton and every 2 months thereafter
- Adilmumap: 40 mg by subcutaneous injection once every two weeks
On the other hand, YRA-1909 from Yongjin Pharm is a new drug based on a naturally extracted from the leaves of Stauntonia hexaphylla (Thunb) Decne. Of course, the effect is expected to be better than Tofacitinib or Etanercept.
If you are a doctor or a patient, which medicine would you prescribe or take?
http://www.yungjin.co.kr
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20160428000982
COPD is an abbreviation for Chronic Obstructive Pulmonary Disease and a category of a disease that blocks the respiratory tract causing lower the speed of the air in the lungs without any other pulmonary diseases or cardiac diseases. As COPD gets more severe, the number of pulmonary alveoli under the terminal bronchiole increases and pulmonary alveoli wall breaks, which is called pulmonary emphysema. We use the term COPD when we can't discriminate the two symptoms.
It is known that more than 90% of the causes of COPD are due to smoking. Air pollution, congenital diseases, and respiratory infections also account for the remaining 10%. COPD is the world's 4th disease and 7th disease in Korea in terms of death rate. The world market capitalization for COPD has been estimated to reach 26.9 billion USD (31.5 trillion KRW) by 2017.
http://www.medgadget.com/2015/06/asthma-and-copd-drug-market-global-industry-analysis-market-size-share-trends-growth-and-forecasts-2010-2017.html
Rheumatoid arthritis is known to occur in around 0.8% of the adult population. There is no way to prevent or cure this disease, but we can slow down the progress. The global market for rheumatoid arthritis medicine is expected to reach 80 billion USD (93.9 trillion KRW) by 2020.
http://www.prnewswire.com/news-releases/rheumatoid-arthritis-market-to-2020---a-crowded-market-characterized-by-modest-growth-300059888.html
Below is the development schedule for COPD and rheumatoid arthritis medicine of Yungjin Pharm.
Development Research for COPD medicine (YPL-001)
- US clinical IND approval (2013. 04)
- Completed US Phase 1 clinical trial (SAD) (2013. 07)
- Completed US Phase 1 clinical trial (MAD) (2014. 02)
- Completed US Phase 2 clinical trial (PoC) US SAB meeting (2014. 01)
- US Phase 2 clinical trial (PoC) approval (2014. 10)
- Registration of US clinical trial (PoC) examination information (ClinicalTrials.gov, 2014. 10)
- Completed of Kick-off-meeting of US Phase 2 clinical trial (PoC) (2014, 10)
- Completed US Phase 2 clinical trial (PoC) IRB approval (2014. 12, 2015 02)
- US Phase 2 clinical trials (PoC) Selected as a new phase drug development project (2015. 01; 3.7 billion KRW)
- US Phase 2 clinical trial (PoC) clinical initiation meeting (2015 03)
- US Phase 2 clinical trial (PoC) is in progress (2016 04 - present)
Development Research for rheumatoid arthritis medicine (YRA-1909)
- Natural product research to push into the US market (2014. 12 - 2019. 11, Ministry of Trade, Industry and Energy: 5 years 3.5 billion KRW)
- Completed mass production study
- Secured GAP mass cultivation site (3,300 square meter) and cultivation: Jangheung-gun, Jeollanam-do
- Research on ensuring equality of raw materials by origin
- Ingredient research (separation, purification etc.)
- Identification of three new ingredients (preparing for patent application)
- selected government task by Ministry of Trade, Industry and Energy (2014 04)
- Production of raw materials and nonclinical toxicity test (2015 02 - present)
- Domestic Phase 2 clinical trial approval (2015.12) and preparations to proceed (present)
Competitive Products for COPD medicine
In contrast, COPD medicine from Yungjin Pharm is a natural-based treatment extracted from Mountain spike speedwell so that patients can easily take it. This medicine has the advantage that the drug acts on the entire lung effectively and aims to function as a cure agent instead of a symptom reliever.
Competitive products for rheumatoid arthritis
You should inject new rheumatoid drugs below as you can read.
- Etanercept: 25 mg by subcutaneous injection twice a week
- Infliximab: 3 to 5 mg / kg by intravenous injection at 0, 2, 6 week of administraton and every 2 months thereafter
- Adilmumap: 40 mg by subcutaneous injection once every two weeks
On the other hand, YRA-1909 from Yongjin Pharm is a new drug based on a naturally extracted from the leaves of Stauntonia hexaphylla (Thunb) Decne. Of course, the effect is expected to be better than Tofacitinib or Etanercept.
If you are a doctor or a patient, which medicine would you prescribe or take?
Brexit - a great chance to purchase stocks in low price
Brexit - a great chance to purchase stocks in low price
The British voted to withdraw from the EU, which they stayed for 43 years. Each stock market around the world are super nervous, because they don't know how much this Brexit will impact the stock market. It is a natural reaction, because none of EU members has not withdrawn from the Europe community.
Do we really have to be super nervous? I don't think it's necessary. KOSPI more deeply plummeted (six times) than these days since 2010. At those moments, it retreated 2.9 - 16.9% but quickly recovered the original KOSPI.
I think, this time, the impact would be much lesser, and the market would be more quickly recovered. The reason is that South Korea exports only 1.4% of the total amount of export to the United Kingdom. England is just 16th country among the whole economic partners of South Korea in terms of the amount of trade volume. Also, if won-yen exchange rate rises the competitiveness of products, which compete to Japan products, from South Korea will be strengthened.
There is, of course, a concern that the UK funds takes around 8.5% of South Korea stock market. If the UK withdraws money from South Korea stock market, it would be severely impact the stock market again making a synergy effect with leaving other countries money. It is still, however, unlikely to happen, and it's just one of a few
Of course, there is also concern that the UK funds account for 8.5% of the domestic stock market. If the UK withdraws money from the Korean stock market, it will be able to shake the stock market again, along with the funds it follows. But this is unlikely to happen, and it's just one of a few scenarios that doesn't seem like occur.
The variability of the market caused by Brexit should be recognized as a bargain sale for blue chips, which only comes maybe once a year. We have to fully harness this moment as a chance to buy stock items that we have carefully watched at a low price.
The British voted to withdraw from the EU, which they stayed for 43 years. Each stock market around the world are super nervous, because they don't know how much this Brexit will impact the stock market. It is a natural reaction, because none of EU members has not withdrawn from the Europe community.
Do we really have to be super nervous? I don't think it's necessary. KOSPI more deeply plummeted (six times) than these days since 2010. At those moments, it retreated 2.9 - 16.9% but quickly recovered the original KOSPI.
I think, this time, the impact would be much lesser, and the market would be more quickly recovered. The reason is that South Korea exports only 1.4% of the total amount of export to the United Kingdom. England is just 16th country among the whole economic partners of South Korea in terms of the amount of trade volume. Also, if won-yen exchange rate rises the competitiveness of products, which compete to Japan products, from South Korea will be strengthened.
There is, of course, a concern that the UK funds takes around 8.5% of South Korea stock market. If the UK withdraws money from South Korea stock market, it would be severely impact the stock market again making a synergy effect with leaving other countries money. It is still, however, unlikely to happen, and it's just one of a few
Of course, there is also concern that the UK funds account for 8.5% of the domestic stock market. If the UK withdraws money from the Korean stock market, it will be able to shake the stock market again, along with the funds it follows. But this is unlikely to happen, and it's just one of a few scenarios that doesn't seem like occur.
The variability of the market caused by Brexit should be recognized as a bargain sale for blue chips, which only comes maybe once a year. We have to fully harness this moment as a chance to buy stock items that we have carefully watched at a low price.
Find blue chips throughout financial statements (5) earnings per share (EPS)
Find blue chips throughout financial statements (5) earnings per share (EPS)
Earning per share (EPS) is the net profit of a company divided by the number of shares. We have to divide the net profit with the number of issued shares (outstanding shares not treasury stocks). The EPS of a company, which has 100 million dollars of net profit and 10 million out standing shares, will be 10 dollars. The higher EPS is, of course, better.
However, the temporarily high EPS is not that good. EPS is also required to be treated in a long-term point of view. We need to review EPS of the past 10 years and check whether it has been increasing continuously. Because these companies have enough room for operating their own business, it is more likely that they would use financial techniques such as purchasing treasury stocks, indicating that they have a potential to rise stock price over the long term.
Earning per share (EPS) is the net profit of a company divided by the number of shares. We have to divide the net profit with the number of issued shares (outstanding shares not treasury stocks). The EPS of a company, which has 100 million dollars of net profit and 10 million out standing shares, will be 10 dollars. The higher EPS is, of course, better.
However, the temporarily high EPS is not that good. EPS is also required to be treated in a long-term point of view. We need to review EPS of the past 10 years and check whether it has been increasing continuously. Because these companies have enough room for operating their own business, it is more likely that they would use financial techniques such as purchasing treasury stocks, indicating that they have a potential to rise stock price over the long term.
Subscribe to:
Posts (Atom)